The enactment this month of the 21st Century Cures Act on top of the draft MDUFA IV user-fee agreement inked between US FDA and industry this summer add a range of mandates and commitments for FDA's device center. Not least among those are guidance documents.
Guidance documents are intended to provide the bread-and-butter of what device companies need to know to get products to the US market and maintain compliance. The device center, on Dec. 22, issued its annual two-tier priority list for in-process guidance documents it hopes to finalize and new draft guidelines it hopes to rollout in FY 2017, which ends Sept. 30, 2017